Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyka LabsBOM:500259 -0.71%51 Days Payable is 138.94 as of Mar. 2026, which is 22% below its 10-year median of 179.21. GuruFocus rates BOM:500259 with a GF Score™ of 51/100 and a GF Value™ of ₹127.34 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, Lyka Labs ranks better than 51.5% on this metric.
Lyka Labs's average Accounts Payable for the
three
months ended in Mar. 2026 was ₹168 Mil. Lyka Labs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹110 Mil.
Hence, Lyka Labs's Days Payable for the
three
months ended in Mar. 2026 was 138.94.
The historical rank and industry rank for Lyka Labs's Days Payable or its related term are showing as below:
BOM:500259'
s Days Payable Range Over the Past 10 Years
Min: 86.86 Med: 179.21 Max: 502.11
Current: 118
During the past 13 years, Lyka Labs's highest Days Payable was 502.11. The lowest was 86.86. And the median was 179.21.
BOM:500259's Days Payable is ranked better than 51.5% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs BOM:500259: 118.00
Lyka Labs's Days Payable
increased
from Mar. 2025 (104.28) to Mar. 2026 (138.94).
It may suggest that Lyka Labsdelayed paying its suppliers.
Lyka Labs Days Payable Related Terms
Lyka Labs Days Payable Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Lyka Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Days Payable distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lyka Labs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyka Labs (BOM:500259) has a Days Payable of 138.94 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lyka Labs and its competitors. This is 22% below median its historical median of 179.21. Over the past decade, Lyka Labs' Days Payable has ranged from 86.86 to 502.11. According to the industry distribution chart, Lyka Labs ranks #340 out of 701 companies in the Biotechnology industry, placing it in the top 48.5%.
Is Lyka Labs' Days Payable too high?
Lyka Labs' current Days Payable of 138.94 is 22% below median its 10-year median of 179.21. Over the past 10 years, this metric has ranged from a low of 86.86 to a high of 502.11. The Biotechnology industry median Days Payable is 112.84. Lyka Labs' value of 138.94 is 23.1% above this industry median. Based on the distribution chart, Lyka Labs ranks #340 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #340 out of 701 companies for Days Payable. This puts Lyka Labs in the upper half of its industry. The industry median Days Payable is 112.84. Lyka Labs' value of 138.94 is 23.1% above this benchmark. Historically, Lyka Labs' own Days Payable has ranged from 86.86 to 502.11 over the past decade. While the company's 10-year median is 179.21 vs. the industry median of 112.84, Lyka Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyka Labs's current Days Payable of 138.94 is 23.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lyka Labs and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyka Labs's current Days Payable is 138.94, which is 22% below median its own 10-year median of 179.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.34, compared to a current price of ₹69.50 — trading 45.4% below its estimated fair value. The current Days Payable is 138.94, which is 22% below median its 10-year median of 179.21 and 23.1% above the Biotechnology industry median of 112.84. Lyka Labs' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Days Payable is 138.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹69.50 is trading 45.4% below its estimated GF Value™ of ₹127.34.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Days Payable: 138.94 (22% below median its 10-year median of 179.21)
GF Value™: ₹127.34 vs. price of ₹69.50 (45.4% below fair value)
Industry Position: 23.1% above the Biotechnology median (#340 of 701)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
51GF Score
Get the complete analysis for BOM:500259
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
